Trial Profile
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Topsalysin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 30 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2008 The expected completion date for this trial is now 1 Sep 2010 according to ClinicalTrials.gov.
- 12 Apr 2008 Status changed from initiated to recruiting according to Scott and White Hospital media release.